Literature DB >> 16805078

Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.

Nobuko Taguchi, Shinya Ito.   

Abstract

QUESTION: One of my male patients is receiving ribavirin-interferon alpha 2B (Pegetron) combination therapy for chronic hepatitis C. His wife recently found out she is 6 weeks pregnant. They are concerned that the medications might have affected his sperm. How should I advise them? ANSWER: To the best of our knowledge, paternal exposure to ribavirin-interferon alpha 2B has no adverse effects on reproduction. Although we do not have sufficient information to confirm this, several pregnancies where the father had been exposed to these medications turned out fine. If an unexpected pregnancy occurs while the father is receiving this therapy, there is no medical indication for terminating the pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16805078      PMCID: PMC1479501     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

Review 1.  EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver.

Authors: 
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

Review 2.  Teratogen update: paternal exposures-reproductive risks.

Authors:  J M Trasler; T Doerksen
Journal:  Teratology       Date:  1999-09

3.  No evidence for mutagenic effects of ribavirin: report of two normal pregnancies.

Authors:  K Hegenbarth; U Maurer; P M Kroisel; P Fickert; M Trauner; R E Stauber
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

4.  Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects.

Authors:  Sebastiano Bianca; Giuseppe Ettore
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-01

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 6.  Hepatitis C treatment update.

Authors:  Brian L Pearlman
Journal:  Am J Med       Date:  2004-09-01       Impact factor: 4.965

Review 7.  Peginterferon alfa-2a: a review of approved and investigational uses.

Authors:  S James Matthews; Christopher McCoy
Journal:  Clin Ther       Date:  2004-07       Impact factor: 3.393

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

Review 9.  Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

Authors:  Michael W Fried; Stephanos J Hadziyannis
Journal:  Semin Liver Dis       Date:  2004       Impact factor: 6.115

Review 10.  The natural history of hepatitis C.

Authors:  Nezam H Afdhal
Journal:  Semin Liver Dis       Date:  2004       Impact factor: 6.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.